SEARCH

SEARCH BY CITATION

References

  • 1
    Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. N Engl J Med 1998; 338: 853860.
  • 2
    Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-1998; the EuroSIDA study. Lancet 2000; 356: 291296.
  • 3
    Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 4
    Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, et al. The influence of with human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949953.
  • 5
    Bica I, McGovern B, Dhar R, Stone D. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 6
    Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as a cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 14.
  • 7
    Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goeddart JJ. Natural history of hepatitis C infection in multi-transfused haemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 602610.
  • 8
    Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 14251431.
  • 9
    DiMartino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 11931199.
  • 10
    Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV Cohort Study. Lancet 2000; 356: 18001805.
  • 11
    Hayashi PH, Flynn N, McCurdy SA, Kuramoto K, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991; 33: 177180.
  • 12
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 10541058.
  • 13
    Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rasada R, Carbo J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179183.
  • 14
    Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of US transplant centres. Transplantation 1998; 65: 11871191.
  • 15
    Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patients in the era of highly active antiretroviral therapy. AIDS 2001; 15: 291292.
  • 16
    Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 17
    Ragni MV, Dodson SF, Hunt SC, Bontempo FA. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999; 93: 11131114.
  • 18
    Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation 2001; 72: 16841688.
  • 19
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 20
    Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347: 284287.
  • 21
    Kuo PC. Reconsideration of HIV as a contraindication to transplantation. Transplantation 2001; 71: 16891689.
  • 22
    Kuo PC, Stock PG. Transplantation in the HIV+ patient. Am J Transplant 2001; 1: 1317.
  • 23
    Banff Schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658663.
  • 24
    Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19: 854859.
  • 25
    Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744749.
  • 26
    Tzakis AG, Cooper MH, Dummer JS, Ragni M, Ward JW, Starzl TE. Transplantation in HIV+ patients. Transplantation 1990; 49: 354358.
  • 27
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18421847.
  • 28
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 16151621.
  • 29
    Perillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicentre study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 15811586.
  • 30
    Mai AL, Yim C, O'Rourke K, Heathcote EJ. The interaction of human immunodeficiency virus and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 1996; 22: 299304.
  • 31
    Bonacini M, Govindarajan S, Redeker AG. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 1991; 86: 570573.
  • 32
    Benhamou Y, Bochet M, Thibault V, Calvez V, Flevet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718723.
  • 33
    Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182189.
  • 34
    Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.
  • 35
    Jain AKB, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841845.
  • 36
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in HIV-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 37
    Hossain MM, Coull JJ, Drusano GL, Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Res 2002; 55: 4152.
  • 38
    Konig V, Bauditz J, Lobeck H, Lusebrink R, Neuhaus P, Blumhart G, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992; 16: 11371143.
  • 39
    Gane EJ, Portmann BC, Naumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 40
    Prieto M, Berenguer M, Rayon M, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 41
    Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JYN, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831838.
  • 42
    Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, Williams R. A randomised study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 14031407.
  • 43
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomised study. Gastroenterology 2003; 124: 642650.
  • 44
    Sheiner PA, Schwartz M, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes lead to increased early recurrence after liver transplantation. Hepatology 1995; 21: 3034.
  • 45
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(Suppl 1): S107S114.
  • 46
    Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, Nalpas B. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998; 29: 1219.
  • 47
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248252.
  • 48
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 49
    Sulkowski MS, Mast EE, Seef LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with of human immunodeficiency virus. Clin Infect Dis 2000; 30(Suppl 1): S77S84.